Suppr超能文献

Mirvetuximab soravtansine(一种靶向叶酸受体α(FRα)的抗体药物偶联物(ADC))与帕博利珠单抗联合用于铂耐药卵巢癌患者的安全性和有效性。

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.

作者信息

Matulonis Ursula A, Vergote Ignace, Moore Kathleen N, Martin Lainie P, Castro Cesar M, Gilbert Lucy, Xia Yu, Method Michael, Stec James, Birrer Michael J, O'Malley David M

机构信息

Dana-Farber Cancer Institute, Boston, MA, USA.

University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.

出版信息

Gynecol Oncol. 2025 Jul 22;200:96-104. doi: 10.1016/j.ygyno.2025.06.016.

Abstract

OBJECTIVE

Evaluate the efficacy and safety of mirvetuximab soravtansine-gynx (MIRV) plus pembrolizumab in dose escalation and expansion cohorts of heavily pretreated patients with platinum-resistant ovarian cancer (PROC).

METHODS

Participants with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease relapsed ≤6 months from last platinum-based treatment received MIRV (6 mg/kg adjusted ideal body weight) and pembrolizumab (200 mg) intravenously once every 3 weeks. Tumor FRα expression thresholds were ≥25 % (dose escalation cohort) and ≥50 % (dose expansion cohort) of cells with ≥2+ membrane staining intensity. The primary efficacy endpoint was objective response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety.

RESULTS

Fifty-six participants received the doublet. Median age was 62 years (range, 40-78). Twenty percent of participants had 3 prior lines of systemic treatment, 43 % had ≥4 prior lines, 43 % had prior bevacizumab exposure, and 41 % had prior PARP inhibitor exposure. Among 55 response-evaluable participants, ORR was 31 % (95 % CI, 19-45), median DOR was 8.0 months (95 % CI, 4.2-NR), and median PFS was 4.2 months (95 % CI, 2.8-5.6). Efficacy persisted in patients with multiple prior lines of treatment. Treatment-emergent adverse events were consistent with the profiles of each agent; the most common were diarrhea (all grades, 57 %; grade 3, 4 %), nausea (55 %; 5 %), and fatigue (50 %; 2 %). Treatment-emergent pneumonitis occurred in 25 % of participants, with grade ≥3 events occurring in 2 (4 %) participants.

CONCLUSIONS

MIRV plus pembrolizumab demonstrated anti-cancer efficacy and a tolerable safety profile in heavily pretreated patients with PROC. However, the efficacy benefit may be mainly attributable to MIRV alone.

摘要

目的

评估mirvetuximab soravtansine-gynx(MIRV)联合帕博利珠单抗在铂耐药卵巢癌(PROC)经大量预处理患者的剂量递增和扩展队列中的疗效和安全性。

方法

复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,其疾病自上次铂类治疗后复发时间≤6个月,每3周静脉注射一次MIRV(6mg/kg调整后的理想体重)和帕博利珠单抗(200mg)。肿瘤FRα表达阈值为膜染色强度≥​​2+的细胞的≥25%(剂量递增队列)和≥50%(剂量扩展队列)。主要疗效终点为客观缓解率(ORR)。次要终点包括缓解持续时间(DOR)、无进展生存期(PFS)和安全性。

结果

56名参与者接受了联合治疗。中位年龄为62岁(范围40-78岁)。20%的参与者接受过3线全身治疗,43%接受过≥4线治疗,43%曾接受过贝伐单抗治疗,41%曾接受过PARP抑制剂治疗。在55名可评估缓解的参与者中,ORR为31%(95%CI,19-45),中位DOR为8.0个月(95%CI,4.2-NR),中位PFS为4.2个月(95%CI,2.8-5.6)。在接受过多次前期治疗的患者中疗效持续存在。治疗中出现的不良事件与每种药物的特征一致;最常见的是腹泻(所有级别,57%;3级,4%)、恶心(55%;5%)和疲劳(50%;2%)。25%的参与者出现治疗中出现的肺炎,2名(4%)参与者出现≥3级事件。

结论

MIRV联合帕博利珠单抗在经大量预处理的PROC患者中显示出抗癌疗效和可耐受安全性。然而,疗效获益可能主要归因于单独使用MIRV。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验